Fresenius SE & Co. KGaA (“Fresenius”) will focus its reporting on financial statements in accordance with International Financial Reporting Standards (IFRS) starting with the 2017 fiscal year on January 1, 2017. The company will then no longer provide U.S. GAAP financial information.

Fresenius, as a publicly traded company based in a European Union member country, is required to prepare and publish its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) pursuant to Section 315a of the German Commercial Code (HGB).

In addition to this compulsory IFRS accounting, Fresenius also publishes consolidated financial statements in accordance with U.S. GAAP. This has provided comparability with the Group’s largest subsidiary, Fresenius Medical Care, which was required to report in accordance with U.S. GAAP under a so-called Pooling Agreement. However, Fresenius Medical Care’s 2016 Annual General Meeting has lifted this obligation.

In the interest of harmonizing the management and accounting of the Fresenius Group and all of its business segments, the Fresenius Group and all of its business segments will report solely in accordance with IFRS starting with the 2017 fiscal year on January 1, 2017.

For the 2016 fiscal year, Fresenius will as in past years provide both U.S. GAAP and IFRS consolidated financial statements.

No significant differences between IFRS and U.S. GAAP financial statements

Past reporting showed only limited differences between the consolidated U.S. GAAP and IFRS accounts of Fresenius SE & Co. KGaA. Historic IFRS figures for the Fresenius Group and its individual business segments are provided on our Investor Relations website.

No effect on the ADR program

The discontinuation of U.S. GAAP reporting will not affect the sponsored Level 1 American Depositary Receipt (ADR) program of Fresenius SE & Co. KGaA in the United States. The ADRs will continue to trade under the FSNUY ticker on the over-the-counter OTCQX International Premier market.